Providing Novel Therapies for Patients with Neurodegenerative Diseases
At Inhibikase Therapeutics, our innovative approach to drug development has resulted in multiple product candidates progressing in development that we believe offer significant new promise to patient populations that currently have no or limited treatment options. Each novel differentiated drug candidate is the result of the application of our proprietary RAMP™ drug innovation and/or prodrug technology engines to the same clinically validated kinase target.
IkT-148009 for Parkinson’s Disease and GI complications
Our lead product candidate, IkT-148009, is a first-in-class, small-molecule medication that targets c-Abl kinase, a clinically validated drug target associated with Parkinson’s disease, to halt progression and reverse functional loss.
IkT-001Pro for Chronic Myeloid Leukemia
IkT-001Pro was developed with the goal of improving the safety of imatinib (Gleevec®), the first FDA-approved Abl kinase inhibitor commonly taken for hematological and gastrointestinal cancers.
IkT-01427 for Progressive Multifocal Leukoencephalopathy
Developed using our RAMP™ technology, the goal of IkT-01427 is to block the entry of the John Cunningham (JC) virus into the cell, thereby preventing the virus from replicating in the body.
We continually collaborate with academic research teams and other third parties to drive our discovery efforts and advance the product candidates in our pipeline.
We actively seek new partnering opportunities with pharmaceutical and biotechnology companies to create innovative new kinase inhibitor drugs that target CNS diseases, including diseases of the brain.